OK TO ENTER: /PR/

RECEI 950-791-6193 CENTRAL FAX CENTER JUN 2 3 2008

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Previously presented) A noninvasive cancer screening method comprising
- a) providing a mixture of proteonic cancer markers from different types of cancer cells, said mixture containing proteonic cancer markers identified and markers not yet identified;
- b) forming polyclonal antibodies against the mixture;
- 5 c) forming a reagent from said polyclonal antibodies;
 - d) obtaining a saliva sample from a human not diagnosed with cancer;
 - e) bringing said saliva sample together with the reagent to form an assay sample, and
 - f) assaying the assay sample by simple ELISA test to determine whether an immunological reaction has occurred in the assay sample,
- wherein ELISA test results higher than a predetermined value are indicative of a positive screening test for cancer.
 - 2. (Previously presented) A method as in claim 1 wherein, in the ELISA test, the human saliva sample is coated on a plate prior to being brought together with the reagent.
 - 3. (Previously presented) A method as in claim 2 wherein the ELISA test results are titer.

- 4-7 (canceled)
- 8. (Previously presented) A method as in claim 1 wherein the polyclonal antibodies are produced in animals.
- 9. (Previously presented) A method as in claim 8 further comprising separating blood containing the polyclonal antibodies from the animals and separating serum containing the polyclonal antibodies therefrom.
- 10. (Previously presented) A method as in claim 9 further comprising forming the reagent from the serum.
- 11. (Previously presented) A method as in claim 1 further comprising centrifuging a human saliva specimen to separate out cells and mucin and collecting the supernatant to form the human saliva sample.
- 12. (Previously presented) A method as in claim 11 further comprising collecting the human saliva specimen.
- 13 15 (canceled)
- 16. (Previously presented) A non-invasive cancer screening method comprising
- a) providing a mixture of proteonic cancer markers obtained from breast, liver, colon, and ovarian cancers, said mixture containing proteonic cancer markers identified and markers not yet identified;
- 5 b) forming polyclonal antibodies against the mixture;

- c) forming a reagent from said polyclonal antibodies;
- d) obtaining a saliva specimen from a human not diagnosed with cancer;
- e) forming a saliva sample from the saliva specimen;
- f) bringing the saliva sample together with the reagent to form an assay sample, and
- g) assaying the assay sample by simple ELISA titer test to determine whether an immunological reaction has occurred in the assay sample,

wherein ELISA titer test results of greater than 1:1,000 are indicative of a positive screening test for cancer.

- 17. (Previously presented) A method as in claim 16 wherein, in the simple ELISA test, the saliva sample is coated on a plate prior to being brought together with the reagent.
- 18. (canceled)
- 19. (canceled)
- 20. (Previously presented) A method as in claim 1 further comprising, in a case where the ELISA test results are indicative of a positive screening test for cancer,
- a) obtaining a second saliva specimen from the human,
- b) forming a second saliva sample from the second saliva specimen,
- 5 c) separating the second saliva sample into a plurality of portions,
 - d) bringing each portion of the second saliva sample together with a reagent produced by providing a mixture of proteonic cancer markers identified and markers not yet identified from a

10

single type of cancer cells, forming polyclonal antibodies against the mixture, and forming the reagent from the polyclonal antibodies, to form an assay sample; and

- e) conducting a simple ELISA test on the assay sample,
 wherein an ELISA test result higher than a predetermined value is indicative of a positive
 screening test for proteonic markers of said cancer cell type.
 - 21 23 (canceled)
 - 24. (currently amended) A method as in claim 20

wherein the plurality of proteonic cancer markers from different types of cancer cells comprise proteonic cancer cell markers made single type of cancer cells is selected from the group consisting of a breast cancer cell line, a lung cancer cell line, a stomach cancer cell line, a liver cancer cell line, a colon cancer cell line, an ovarian cancer cell line, a cervical cancer cell line, a mouth/pharynx cancer cell line, a skin cancer cell line, a pancreatic cancer cell line, a testes cancer cell line, a brain tumor cell line, and a prostate cancer cell line.